Current and Emerging Role of Antibody–Drug Conjugates in HER2-Negative Breast Cancer
Rachel O. Abelman(Massachusetts General Hospital), Aditya Bardia(Harvard University), Laura M. Spring(Massachusetts General Hospital), Phoebe Ryan(Harvard University), Jennifer C Keenan(Harvard University)
Cited by 4
Related Papers
Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab
|Cancer Discovery|2021|241
Mechanisms of Resistance to Antibody–Drug Conjugates
|Cancers|2023|135
A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer
|Cancer Discovery|2018|116
HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial.
|Journal of Clinical Oncology|2019|82